Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Company Descriptionsort icon Status Initial Date
<a href="/venture-capital/all-companies/selecta-biosciences-inc">Selecta Biosciences, Inc.</a> Developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Private 2008 View Profile
<a href="/venture-capital/all-companies/oasys-water-inc">Oasys Water, Inc.</a> Developing innovative solutions for water treatment and desalination in industrial markets around the globe. Private 2009 View Profile
<a href="/venture-capital/all-companies/t2-biosystems-inc">T2 Biosystems, Inc.</a> Developing innovative diagnostic products to improve patient health. Public 2006 View Profile
<a href="/venture-capital/all-companies/quanterix-corporation">Quanterix Corporation</a> Developing ground-breaking tools in high definition diagnostics. Private 2007 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Developing and delivering diagnostic solutions to aid in the clinical management of heart failure and related disorders. Public 2000 View Profile
<a href="/venture-capital/all-companies/tangent-medical-technologies-inc">Tangent Medical Technologies Inc.</a> Developing and commercializing IV therapy products. Private 2011 View Profile
<a href="/venture-capital/all-companies/seventh-sense-biosystems-inc">Seventh Sense Biosystems, Inc.</a> Developing an array of products based on the company's proprietary TAP™ (Touch Activated Phlebotomy) painless blood collection platform. Private 2007 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing Accurins, its novel targeted therapeutics. Public 2007 View Profile
<a href="/venture-capital/all-companies/taris-biomedical-inc">TARIS Biomedical, Inc.</a> Developing a pipeline of innovative treatments for bladder diseases. Private 2008 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/quantum-designs">Quantum Designs</a> Commercializing breakthrough, innovative products in human nutrition. Private 2012 View Profile
<a href="/venture-capital/all-companies/novomer-inc">Novomer, Inc.</a> Commercializing a family of low-cost, high-performance, sustainable polymers and other chemicals. Private 2007 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Public 2006 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Advancing the science and technology of corneal crosslinking and refractive correction. Private 2009 View Profile
<a href="/venture-capital/all-companies/pronutria">Pronutria</a> Transforming medicine with ProNutrein™ products, protein nutrients identified in the human diet, for the dietary management of disease. Private 2010 View Profile